Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after lentiviral-based CAR T-cell therapy
2023-508128-37-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of tisagenlecleucel, rapcabtagene autoleucel and durcabtagene autoleucel in hematopoietic malignancies and Immune disorder, sponsored by Novartis. Primary endpoint: Delayed safety events related to prior CAR T-cell therapy. Planned start Jul 2017; status: authorised.
02
Drugs
tisagenlecleucelrapcabtagene autoleuceldurcabtagene autoleucel
03
Conditions
hematopoietic malignanciesImmune disorder
Beyond the preview
Go deeper on 2023-508128-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508128-37-00.